Search

Displaying results 6111 - 6120 of 10000 in total
  1. Drug

    Artemin

    go.drugbank.com/drugs/DB15438
    Investigational

    Artemin is under investigation in clinical trial NCT01842126 (Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)).

  2. Drug

    Navoximod

    go.drugbank.com/drugs/DB15439
    Investigational

    Navoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  3. Drug

    Elexacaftor

    go.drugbank.com/drugs/DB15444
    ApprovedInvestigational

    [L9395] Elexacaftor is considered a next-generation CFTR corrector as it possesses both a different structure and mechanism as compared to first generation correctors like tezacaftor. … Elexacaftor (previously VX-445) is a small molecule, next-generation corrector of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Acumapimod

    go.drugbank.com/drugs/DB15448
    Investigational

    Acumapimod is under investigation in clinical trial NCT02926326 (The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers).

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    Citarinostat

    go.drugbank.com/drugs/DB15449
    Investigational

    Citarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).

    Categories: Heterocyclic Compounds, 1-RingSynonyms: (2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide)
  6. Drug

    Tallimustine

    go.drugbank.com/drugs/DB15466
    Experimental

    Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. … [A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity

  7. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2).

    Categories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsSynonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY
  8. Drug

    Frangula purshiana bark

    go.drugbank.com/drugs/DB15478
    Approved

    Mixtures: Le 100 B, C Ottways Lax Tab
  9. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABA<sub>A</sub> receptors. … This approval was based on favorable results from 2 phase 3 clinical trials.[L47691]

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  10. Drug

    BOS172722

    go.drugbank.com/drugs/DB15498
    Investigational

    BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent.

    Categories: Heterocyclic Compounds, 1-Ring